Woojung Bio Inc
215380
Company Profile
Business description
Woojung Bio Inc is engaged in the research and development of natural science and engineering. The company operates in bio business and infection control business. The new drug development cluster is established to provide customized data for rapid efficacy evaluation, safety evaluation, and analysis testing required for new drug development. The infection control business is a virtuous cycle business that implements space sterilization and infection prevention facilities in hospitals and other special facilities.
Contact
593-8 Dongtan Giheung-ro
Yeongcheon-dong, Woojung Bio New Drug Cluster
Gyeonggi-do
Hwaseong-si
KORT: +82 312805200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
142
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,161.30 | 3.00 | 0.03% |
| CAC 40 | 8,112.02 | 146.92 | -1.78% |
| DAX 40 | 24,959.06 | 338.07 | -1.34% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,195.35 | 39.94 | -0.39% |
| HKSE | 26,563.90 | 281.06 | -1.05% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,348.59 | 234.98 | -0.44% |
| NZX 50 Index | 13,515.25 | 65.04 | -0.48% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,841.70 | 5.10 | 0.06% |
| SSE Composite Index | 4,114.00 | 12.09 | 0.29% |